

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 September 2008 (04.09.2008)

PCT

(10) International Publication Number
WO 2008/104595 A1

(51) International Patent Classification:

A61K 31/5377 (2006.01) A61P 35/00 (2006.01)
C07D 295/00 (2006.01)

(21) International Application Number:

PCT/EP2008/052443

(22) International Filing Date:

28 February 2008 (28.02.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

07103346.8 1 March 2007 (01.03.2007) EP

(71) Applicants (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **VERNALIS (R & D) LTD.** [GB/GB]; Oakdene Court, 613 Reading Road, Winnersh, Berkshire RG41 5UA (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DRYSDALE, Martin James** [GB/GB]; Vernalis (R & D) Ltd., Oakdene Court, 613 Reading Road, Winnersh, Berkshire RG41 5UA (GB). **DYMOCK, Brian William** [GB/SG]; S*BIO Pte Ltd., 1 Science Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore 117528 (SG). **KRELL, Christoph** [CH/CH]; Breisacherstrasse 71/2, CH-4057 Basel (CH). **MUTZ, Michael** [DE/DE]; Mozartstrasse

33, 79104 Freiburg (DE). **PETERSEN, Holger** [DE/DE]; Akazienweg 1, 79591 Eimeldingen (DE). **ZHENG, Weijia** [CN/US]; Novartis Institutes for BioMedical, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).

(74) Agent: **GRAFF, Alan**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: ACID ADDITION SALTS, HYDRATES AND POLYMORPHS OF 5-(2,4-DIHYDROXY-5-ISO-PROPYL-PHENYL)-4-(4-MORPHOLIN-4-YLMETHYL-PHENYL)-ISOXAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE AND FORMULATIONS COMPRISING THESE FORMS

(57) Abstract: The present invention relates to new salt forms of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-yl-methyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, tartrate, phosphate and hemi fumarate salt thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-yl-methyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.

WO 2008/104595 A1